<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02832297</url>
  </required_header>
  <id_info>
    <org_study_id>088-CL-01</org_study_id>
    <nct_id>NCT02832297</nct_id>
  </id_info>
  <brief_title>Prospective Outcomes Study: Vectra® DA Guided Care Compared to Usual Care</brief_title>
  <official_title>Prospective Outcomes Study: Vectra® DA Guided Care Compared to Usual Care</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Crescendo Bioscience</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Crescendo Bioscience</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this 12-month multi-center prospective, site-randomized, two-arm trial, approximately 318
      biologic-naïve subjects with RA who are candidates for treatment intensification due to
      inadequate response to MTX monotherapy will be enrolled at up to 60 study sites.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To determine whether a strategy of Vectra DA guided care (Arm A), compared with usual care
      (Arm B), achieves non-inferior clinical outcomes while reducing the cost of treatment in
      patients with active RA and an inadequate response to MTX monotherapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 2016</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in DAS28 at Month 6</measure>
    <time_frame>Baseline to 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects using any biologic DMARD or JAK inhibitor to Month 6</measure>
    <time_frame>Baseline to 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with ACR20 response at Month 6</measure>
    <time_frame>Baseline to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HAQ-DI score at Month 6</measure>
    <time_frame>Baseline to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with radiographic non-progression at 12 months</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>Radiographic non-progression will be defined as change in modified total Sharp score (ΔmTSS) ≤0.5 units from baseline to Month 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total cost of RA-related treatment, in US dollars, at Month 6</measure>
    <time_frame>Baseline to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total cost of RA-related treatment, in US dollars, at Month 12</measure>
    <time_frame>Baseline to 12 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Percentage of subjects with low disease activity (DAS28 &lt;3.2) at Month 6</measure>
    <time_frame>Baseline to 6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of subjects with low disease activity (DAS28 &lt;3.2) at Month 12</measure>
    <time_frame>Baseline to 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of subjects with EULAR response at Month 6</measure>
    <time_frame>Baseline to 6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of subjects with EULAR response at Month 12</measure>
    <time_frame>Baseline to 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of subjects with ACR50 response at Month 6</measure>
    <time_frame>Baseline to 6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of subjects with ACR50 response at Month 12</measure>
    <time_frame>Baseline to 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in mTSS at Month 12</measure>
    <time_frame>Baseline to 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in HAQ-DI score at Month 12</measure>
    <time_frame>Baseline to 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of subjects with SAE</measure>
    <time_frame>Baseline to 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in work productivity as measured by the WPS-RA at Month 6</measure>
    <time_frame>Baseline to 6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in work productivity as measured by the WPS-RA at Month 12</measure>
    <time_frame>Baseline to 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in health related QOL as measured by SF-36 at Month 6</measure>
    <time_frame>Baseline to 6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in health related QOL as measured by SF-36 at Month 12</measure>
    <time_frame>Baseline to 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in health related QOL as measured by EQ-5D-5L at Month 6</measure>
    <time_frame>Baseline to 6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in health related QOL as measured by EQ-5D-5L at Month 12</measure>
    <time_frame>Baseline to 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of subjects Incremental cost-effectiveness ratio (ICER) in terms of cost per QALY gained at Month 12</measure>
    <time_frame>Baseline to 12 months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">318</enrollment>
  <condition>Arthritis, Rheumatoid</condition>
  <arm_group>
    <arm_group_label>Vectra DA (Arm A)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Treatment intensification with non-biologic DMARDS guided by Vectra DA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual care (Arm B)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Treatment intensification by usual care without using Vectra DA</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Vectra DA</intervention_name>
    <arm_group_label>Vectra DA (Arm A)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Usual Care</intervention_name>
    <arm_group_label>Usual care (Arm B)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects will be eligible to participate in the study if they meet all the following
        criteria:

          1. Willing and able to sign an ICF

          2. Age 18 to 80 years at enrollment

          3. Meets the 2010 ACR/EULAR criteria and/or 1987 criteria for RA, as determined by a
             board-certified rheumatologist ≥3 months prior to enrollment

          4. Received uninterrupted treatment with weekly MTX begun ≥3 months prior to enrollment,
             at a stable dose of ≥15 mg per week for at least 4 weeks prior to enrollment. A
             history of therapy with split dose oral MTX or parenteral MTX is acceptable only if
             the weekly MTX dose was always ≤20 mg/week during the 3 months prior to enrollment.

          5. CDAI &gt;10 as assessed by the Investigator at screening

          6. At least 3 swollen joints (SJC ≥3) and 3 tender joints (TJC ≥3) out of 28 joints as
             assessed by the Investigator at screening

          7. Must be eligible for treatment intensification with non-biologic and biologic DMARDs

          8. Documented evidence of seropositivity (RF and/or anti-CCP antibodies). Seronegative
             subjects are allowed if erosive disease attributable to RA is documented on X-rays.

        Exclusion Criteria:

        Subjects will be ineligible to participate in the study if they meet any of the following
        criteria:

          1. Use of a non-biologic DMARD other than MTX within 3 months prior to enrollment

          2. MTX administered SQ or as an oral split dose at &gt;20 mg/week any time during the 3
             months prior to enrollment

          3. Two or more DMARDs used in combination (i.e., concomitantly), including but not
             limited to: MTX, HCQ, SSZ, LEF, cyclosporine, azathioprine, gold or penicillamine any
             time prior to enrollment

          4. Biologic DMARD or JAKi use any time prior to enrollment

          5. Any contraindication to use of MTX, HCQ, LEF or biologic DMARDs

          6. Opiate use during the 2 weeks prior to enrollment

          7. Oral corticosteroids during the month prior to enrollment at a dosage &gt;10 mg/day
             prednisone (or equivalent) or at a non-stable dose ≤10 mg/day prednisone (or
             equivalent)

          8. MTX intolerance prior to enrollment that limits its use

          9. Inflammatory joint disease (other than RA) or any other systemic autoimmune disorder.
             (Osteoarthritis is not a basis for exclusion.)

         10. Primary or secondary immunodeficiency

         11. Active infection (excluding fungal infection of nail beds); or acute or chronic
             infection requiring hospitalization or treatment with parenteral systemic antibiotics
             within one month of enrollment or treatment with oral antibiotics within 2 weeks of
             enrollment

         12. IA, intravenous or IM corticosteroids during the month prior to enrollment

         13. Initiation or non-stable dosing of NSAIDs within 2 weeks prior to enrollment

         14. Vectra DA testing within 3 months prior to enrollment

         15. Live vaccine within 90 days of enrollment

         16. Active substance abuse or psychiatric illness likely to interfere with protocol
             conduct

         17. History of severe allergic or anaphylactic reaction to any monoclonal antibody therapy

         18. Known infection with HIV (HIV testing will not be a requirement for trial entry); a
             past or current history of hepatitis B virus or hepatitis C virus infection

         19. History of malignancy within the past five years or any evidence of persistent
             malignancy, except fully excised basal cell or squamous cell carcinomas of the skin,
             or cervical carcinoma in situ that has been treated or excised in a curative procedure

         20. Pregnancy or inadequate contraception in women of childbearing potential

         21. Breast feeding or lactating

         22. Medical, psychiatric, cognitive or other conditions that, in the opinion of the
             Investigator, may compromise the ability of the subject to understand the study
             information, to give informed consent, to comply with the trial protocol, or to
             complete the study

         23. Presently enrolled in another clinical trial

         24. Vectra DA score at screening that is outside the applicable range as required for
             subject enrollment

        Note: Screening for TB is not required for subjects participating in the study. If an
        Investigator is considering a subject for treatment with a biologic DMARD in the study,
        guidelines for TB screening need to be followed.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>David Chernoff, MD</last_name>
    <phone>650-351-3056</phone>
    <email>dchernoff@crescendobio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rheumatology Associates of North Alabama PC</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801-4414</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>256-704-7098</phone>
    </contact>
    <investigator>
      <last_name>William J Shergy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Copeland Redyy Rheumatology</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91910</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>619-427-1721</phone>
    </contact>
    <investigator>
      <last_name>Dana Reddy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medvin Clinical Research</name>
      <address>
        <city>Covina</city>
        <state>California</state>
        <zip>91723</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>626-869-5730</phone>
    </contact>
    <investigator>
      <last_name>Samy Metyas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Western Connecticut Health Network</name>
      <address>
        <city>Danbury</city>
        <state>Connecticut</state>
        <zip>06810</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>203-794-5610</phone>
    </contact>
    <investigator>
      <last_name>Michael Spiegel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Delaware Arthritis</name>
      <address>
        <city>Lewes</city>
        <state>Delaware</state>
        <zip>19958</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>302-644-2633</phone>
    </contact>
    <investigator>
      <last_name>Jose Pando, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Howard University</name>
      <address>
        <city>Washington, D.C.</city>
        <state>District of Columbia</state>
        <zip>20060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>202-865-3326</phone>
    </contact>
    <investigator>
      <last_name>Mercedes Quinones, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Robert W. Levin, MD</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>727-734-6631</phone>
    </contact>
    <investigator>
      <last_name>Robert Levin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arthritis Research Associates of Florida</name>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <zip>34684</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>727-210-2555</phone>
    </contact>
    <investigator>
      <last_name>Anthony Sebba, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kenneth Stark, MD</name>
      <address>
        <city>Tavares</city>
        <state>Florida</state>
        <zip>32778</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>352-343-7735</phone>
    </contact>
    <investigator>
      <last_name>Kenneth Stark, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Graves Gilbert Clinic</name>
      <address>
        <city>Bowling Green</city>
        <state>Kentucky</state>
        <zip>42101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>270-393-2786</phone>
    </contact>
    <investigator>
      <last_name>Asad Fraser, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rheumatology Associates of Baltimore</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21286</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>The Center for Rheumatology and Bone Research</name>
      <address>
        <city>Wheaton</city>
        <state>Maryland</state>
        <zip>20902</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>301-942-7833</phone>
    </contact>
    <investigator>
      <last_name>Paul DeMarco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>734-647-8173</phone>
    </contact>
    <investigator>
      <last_name>Elena Schiopu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>June DO, PC</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48910</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>517-272-9727</phone>
    </contact>
    <investigator>
      <last_name>Joshua June, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beals institute PC</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48917</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>517-886-5466</phone>
    </contact>
    <investigator>
      <last_name>Patricia Cagnoli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shores Rheumatology, P.C.</name>
      <address>
        <city>Saint Clair Shores</city>
        <state>Michigan</state>
        <zip>48081</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>586-777-7577</phone>
    </contact>
    <investigator>
      <last_name>Amar Majjihoo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North Mississippi Medical Center</name>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <zip>38801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>662-377-5131</phone>
    </contact>
    <investigator>
      <last_name>Charles King, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Timothy Kelly, MD</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Summit Medical Group</name>
      <address>
        <city>Berkeley Heights</city>
        <state>New Jersey</state>
        <zip>07922</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>908-277-8747</phone>
    </contact>
    <investigator>
      <last_name>Lauren Kennish, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prospect Medical Offices Valley Medical Group</name>
      <address>
        <city>Midland Park</city>
        <state>New Jersey</state>
        <zip>07432</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>201-444-4530</phone>
    </contact>
    <investigator>
      <last_name>Evan Leibowitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Overlook Medical Center Wound Healing Center</name>
      <address>
        <city>Summit</city>
        <state>New Jersey</state>
        <zip>07901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>908-522-6156</phone>
    </contact>
    <investigator>
      <last_name>Elliott Rosenstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rheumatology Associates of Long Island</name>
      <address>
        <city>Smithtown</city>
        <state>New York</state>
        <zip>11787</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>631-360-7778</phone>
    </contact>
    <investigator>
      <last_name>Peter Rumore, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>PMG Research of Salisbury</name>
      <address>
        <city>Salisbury</city>
        <state>North Carolina</state>
        <zip>28144</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Rakesh Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carolina Specialty Care</name>
      <address>
        <city>Statesville</city>
        <state>North Carolina</state>
        <zip>28625</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>704-872-8711</phone>
    </contact>
    <investigator>
      <last_name>Bob Wodecki, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>PMG Research of Wilmington</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>910-815-6108</phone>
    </contact>
    <investigator>
      <last_name>Ronald George, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Paramount Medical Research, LLC</name>
      <address>
        <city>Middleburg Heights</city>
        <state>Ohio</state>
        <zip>44130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>440-826-0742</phone>
    </contact>
    <investigator>
      <last_name>Isam Diab, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southern Ohio Rheumatology</name>
      <address>
        <city>Wheelersburg</city>
        <state>Ohio</state>
        <zip>45694</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>740-355-8562</phone>
    </contact>
    <investigator>
      <last_name>Rajesh Kataria, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dr. Alan Kivitz</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635-1018</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>814-693-0300</phone>
      <email>altoonaresearch@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Alan Kivitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center of Reading, LLC</name>
      <address>
        <city>Wyomissing</city>
        <state>Pennsylvania</state>
        <zip>19610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>610-375-2466</phone>
    </contact>
    <investigator>
      <last_name>Robert Griffin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carolina Health Specialist</name>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <zip>29572</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>843-497-5929</phone>
    </contact>
    <investigator>
      <last_name>Douglas Conaway, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Tennesee Health Science</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>901-516-2212</phone>
    </contact>
    <investigator>
      <last_name>Syed Hasan Raza, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southwest Rheumatology Research LLC</name>
      <address>
        <city>Mesquite</city>
        <state>Texas</state>
        <zip>75150</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>972-288-2600</phone>
    </contact>
    <investigator>
      <last_name>Atul Singhal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Accurate Clinical Research</name>
      <address>
        <city>Nassau Bay</city>
        <state>Texas</state>
        <zip>77058</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>281-240-1045</phone>
    </contact>
    <investigator>
      <last_name>Prashanth Sunkureddi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arthritis Clinic of Central Texas</name>
      <address>
        <city>San Marcos</city>
        <state>Texas</state>
        <zip>78666</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>608-848-8900</phone>
    </contact>
    <investigator>
      <last_name>Alissa Hassan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arthritis Clinic of Northern VA, PC</name>
      <address>
        <city>Arlington</city>
        <state>Virginia</state>
        <zip>22205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>703-525-3069</phone>
    </contact>
    <investigator>
      <last_name>Phillip Kempf, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arthritis &amp; Rheumatic Disease</name>
      <address>
        <city>Burke</city>
        <state>Virginia</state>
        <zip>22015</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>703-425-4435</phone>
    </contact>
    <investigator>
      <last_name>Neil Stahl, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Western Washington Arthritis Clinic</name>
      <address>
        <city>Bothell</city>
        <state>Washington</state>
        <zip>98021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>425-248-2635</phone>
    </contact>
    <investigator>
      <last_name>Jeff Peterson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Polyclinic</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>206-860-5433</phone>
    </contact>
    <investigator>
      <last_name>Anthony Krajcer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arthritis Northwest, P.L.L.C</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>509-462-2808</phone>
    </contact>
    <investigator>
      <last_name>Howard Kenney, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gundersen Clinic, Ltd.</name>
      <address>
        <city>Onalaska</city>
        <state>Wisconsin</state>
        <zip>54650</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>608-775-7008</phone>
    </contact>
    <investigator>
      <last_name>Carol Danning, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 7, 2016</study_first_submitted>
  <study_first_submitted_qc>July 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2016</study_first_posted>
  <last_update_submitted>July 3, 2017</last_update_submitted>
  <last_update_submitted_qc>July 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

